The Art Of Cutting Costs Without Jeopardizing Growth: An Interview With Merck Serono's Belén Garijo
Executive Summary
Having emerged from a radical restructuring with new senior management, a revamped portfolio and a strategic ambition to morph into an oncology powerhouse on the back of its emerging markets business, CEO Belén Garijo says Merck Serono is poised to enter its growth phase.
You may also be interested in...
Merck KGAA Rebuilds Its R&D Portfolio, Re-Aligns Into Three Businesses
The diversified German company eschews the tightening of focus seen in other European pharmaceutical companies, but does subdivide its business into three units: health care, life sciences and performance materials.
Merck KGAA Rebuilds Its R&D Portfolio, Re-Aligns Into Three Businesses
The diversified German company eschews the tightening of focus seen in other European pharmaceutical companies, but does subdivide its business into three units: health care, life sciences and performance materials.
Merck KGaA Finds R&D Nuggets: Plans Further Atacicept Studies In Lupus
A discussion with internal and external experts restarts clinical development of atacicept for lupus after a two-year hiatus.